Histopathology and Feline Pancreatic Lipase Immunoreactivity in Inflammatory, Hyperplastic and Neoplastic Pancreatic Diseases in Cats. (January 2020)

• Record Type: Journal Article
• Authors: Törner, K.; Staudacher, M.; Tress, U.; Weber, C.N.; Stadler, C.; Grassinger, J.M.; Müller, E.; Aupperle-Lellbach, H.
• Is Part Of: Journal of comparative pathology. Volume 174(2020)
• Page Start: 63
• Page End: 72
• Publication Date: 2020-01
• Subjects: cat -- feline pancreatic lipase immunoreactivity -- pancreatitis -- tumour; Veterinary pathology -- Periodicals; Veterinary therapeutics -- Periodicals; Pathology, Comparative -- Periodicals; Therapeutics -- Periodicals; Pathology, Veterinary -- Periodicals; 636.089607
• DOI: 10.1016/j.jcpa.2019.10.195
• Languages: English
• ISSNs: 0021-9975

Abstract

Summary: The most common pancreatic diseases in cats are pancreatitis and exocrine pancreatic insufficiency (EPI). Non-invasive methods, such as serological quantification of feline pancreatic lipase immunoreactivity (fPLI), are often used in the diagnosis of pancreatitis. Previous studies have compared fPLI concentrations with histopathology, considered to be the gold standard for diagnosis of feline pancreatitis. However, fPLI concentrations in cats suffering from pancreatic tumours were rarely described. The aim of the present study was to determine the sensitivity and specificity of an in-house enzyme-linked immunosorbent assay (ELISA) for the quantification of fPLI in serum samples based on histopathological findings in cats diagnosed with various pancreatic diseases. Pancreatic biopsy samples from 80 cats were included. Five groups were defined on the basis of pancreatic histopathology: group 1, normal pancreas; group 2, nodular hyperplasia; group 3, mild pancreatitis; group 4, marked (moderate/severe) pancreatitis; and group 5, pancreatic neoplasia. Serum samples from all cats were tested by fPLI ELISA (<3.6 μg/l normal, 3.6–5.3 μg/l questionable, >5.3 μg/l pancreatitis). In group 1 ( n = 19), serum fPLI values were within the reference interval in 74% of cases and in group 2 ( n = 9) in 78%. Cats with mild pancreatitis ( n = 23), marked pancreatitis ( n = 11) and pancreatic neoplasms ( n = 18) had significantly increased fPLI concentrations compared with group 1 ( P = 0.004/0.001/≤0.0001). Cats with nodular hyperplasia had significantly lower fPLI values than cats with marked pancreatitis ( P = 0.048) or tumours ( P = 0.002). Serum fPLI concentrations in group 3 were <3.6 μg/l ( n = 6), 3.6–5.3 μg/l ( n = 4) and >5.3 μg/l ( n = 13). Calculated test sensitivity for mild pancreatitis was fPLI >3.5 μg/l: 73.9% and fPLI >5.3 μg/l: 56.5%. In group 4 ( n = 11), seven of nine cats (77.8%) with marked purulent pancreatitis had elevated fPLI. In group 4, a sensitivity of 81.8% was detected for fPLI >3.5 μg/l and 63.6% for fPLI >5.3 μg/l. Two cats with marked non-purulent pancreatitis had elevated fPLI, while two cats with marked purulent pancreatitis had normal fPLI values (<3.6 μg/l). In group 5, one cat with pancreatic adenoma and one with pancreatic acinar carcinoma had normal fPLI concentrations. The other cats with pancreatic adenoma (solid, n = 1; cystic, n = 4) or carcinoma (solid, n = 9; cystic, n = 2) had elevated or high fPLI values (4.1 to >40 μg/l, median 21.2 μg/l), probably caused by additional inflammation. The results of the present study confirm the importance of detailed histopathological characterization for the interpretation of clinical signs and fPLI values in feline pancreatitis. Primary pancreatic neoplasms may also lead to elevated fPLI concentrations as there is concurrent pancreatitis in most cases. However, severe pancreatic diseases, such as chronic non-purulent pancreatitis or tumours without inflammation, may result in normal fPLI values.